Anna Kamocka

Anna Kamocka

Auto-generated profile, based on publicly available information

Anna Kamocka

Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
AMAlexander D. Miras
Alexander D. Miras
AKAnna Kamocka
Anna Kamocka
DPDarshan Patel
Darshan Patel
SDSimon Dexter
Simon Dexter
IFIan Finlay
Ian Finlay
RWRichard Welbourn
Richard Welbourn
The National Bariatric Surgery Registry (NBSR) is the largest bespoke database in the field in the United Kingdom. Our aim was to analyze the NBSR to determine whether the effects of obesity surgery on associated co-morbidities observed in small randomized controlled clinical trials could be replicated in a "real life" setting within U.K. healthcare. United Kingdom. All NBSR entries for operations between 2000 and 2015 with associated demographic and co-morbidity data were analyzed retrospectively. A total of 50,782 entries were analyzed. The patients were predominantly female (78%) and white European with a mean age of 45 ± 11 years and a mean body mass index of 48 ± 8 kg/m2. Over 5 years of follow-up, statistically significant reductions in the prevalence of type 2 diabetes, hypertension, dyslipidemia, sleep apnea, asthma, functional impairment, arthritis, and gastroesophageal reflux disease were observed. The "remission" of these co-morbidities was evident 1 year postoperatively and reached a plateau 2 to 5 years after surgery. Obesity surgery was particularly effective on functional impairment and diabetes, almost doubling the proportion of patients able to climb 3 flights of stairs and halving the proportion of patients with diabetes related hyperglycemia compared with preoperatively. Surgery was safe with a morbidity of 3.1% and in-hospital mortality of .07% and a reduced median inpatient stay of 2 days, despite an increasingly sick patient population. Obesity surgery in the U.K. results not only in weight loss, but also in substantial improvements in obesity-related co-morbidities. Appropriate support and funding will help improve the quality of the NBSR data set even further, thus enabling its use to inform healthcare policy.

4 August 2022 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
AKAnna Kamocka
Anna Kamocka
SCSwathikan Chidambaram
Swathikan Chidambaram
SESimon Erridge
Simon Erridge
GVGauri Vithlani
Gauri Vithlani
AMAlexander D. Miras
Alexander D. Miras
SPSanjay Purkayastha
Sanjay Purkayastha
Background: Roux-en-Y gastric bypass (RYGB) is a gold-standard procedure for treatment of obesity and associated comorbidities. No consensus on the optimal design of this operation has been achieved, with various lengths of bypassed small bowel limb lengths being used by bariatric surgeons. This aim of this systematic review and meta-analysis was to determine whether biliopancreatic limb (BPL) length in RYGB affects postoperative outcomes including superior reduction in weight, body mass index (BMI), and resolution of metabolic comorbidities associated with obesity. Methods: A systematic search of the literature was conducted up until 1st June 2021. Meta-analysis of primary outcomes was performed utilising a random-effects model. Statistical significance was determined by p value < 0.05. Results: Ten randomised controlled trials were included in the final quantitative analysis. No difference in outcomes following short versus long BLP in RYGB was identified at 12–72 months post-operatively, namely in BMI reduction, remission or improvement of type 2 diabetes mellitus, hypertension, dyslipidaemia, and complications (p > 0.05). Even though results of four studies showed superior total body weight loss in the long BPL cohorts at 24 months post-operatively (pooled mean difference −6.92, 95% CI –12.37, −1.48, p = 0.01), this outcome was not observed at any other timepoint. Conclusion: Based on the outcomes of the present study, there is no definitive evidence to suggest that alteration of the BPL affects the quantity of weight loss or resolution of co-existent metabolic comorbidities associated with obesity.

18 November 2014 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
MDMatt J. D. Dunstan
Matt J. D. Dunstan
EMEmma J. Molena
Emma J. Molena
KRKumaran Ratnasingham
Kumaran Ratnasingham
AKAnna Kamocka
Anna Kamocka
NSNatasha C. Smith
Natasha C. Smith
SIShashi Irukulla
Shashi Irukulla

8 August 2019 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
AKAnna Kamocka
Anna Kamocka
EMEmma Rose McGlone
Emma Rose McGlone
BPBelén Pérez-Pevida
Belén Pérez-Pevida
KMKrishna Moorthy
Krishna Moorthy
SHSherif Hakky
Sherif Hakky
AAAhmed Rashid Ahmed
Ahmed Rashid Ahmed
Background An excessively long-blind end of the alimentary limb following a Roux-en-Y gastric bypass (RYGB), known as a ‘candy cane’ (CC), may cause symptoms including abdominal pain, regurgitation and vomiting. Very few studies have examined the efficacy of surgical resection of the CC. Objectives The aim of this study was to assess sensitivity of preoperative diagnostic tools for CC, as well as perioperative outcomes and symptom resolution after CC revision surgery. Setting High volume bariatric centre of excellence, United Kingdom. Methods Observational study of CC revisions from 2010 to 2017. Results Twenty-eight CC revision cases were identified (mean age 45 ± 9 years, female preponderance 9:1). Presenting symptoms were abdominal pain (86%), regurgitation/vomiting (43%), suboptimal weight loss (36%) and acid reflux (21%). Preoperative tests provided correct diagnosis in 63% of barium contrast swallows, 50% of upper gastrointestinal endoscopies and 29% computed tomographies. Patients presenting with pain had significantly higher CC size as compared with pain-free group (4.2 vs. 2 cm, p = 0.001). Perioperative complications occurred in 25% of cases. Complete or partial symptom resolution was documented in 73% of patients undergoing CC revision. Highest success rates were recorded in the regurgitation/vomiting group (67%). Conclusion Surgical revision of CC is associated with good symptom resolution in the majority of patients, especially those presenting with regurgitation/vomiting. However, it carries certain risk of complications. CC diagnosis may frequently be missed; hence more than one diagnostic tool should be considered when investigating symptomatic patients after RYGB.

1 February 2021 in Efficacy and Mechanism Evaluation
Verified
Journal Article
Open access
PDF file
AMAlexander D. Miras
Alexander D. Miras
AKAnna Kamocka
Anna Kamocka
TTTricia Tan
Tricia Tan
BPBelén Pérez-Pevida
Belén Pérez-Pevida
HCHarvinder Chahal
Harvinder Chahal
FRFrancesco Rubino
Francesco Rubino
Background: Roux-en-Y gastric bypass is recognised as a standard of care in the treatment of diabetes mellitus and obesity. However, the optimal length of the Roux-en-Y gastric bypass limbs remains controversial, with substantial variation in practice. Specifically, a longer biliopancreatic limb length of 150 cm (‘long limb’) has been hypothesised to be better for the treatment of diabetes mellitus because it increases the postprandial secretion of gut hormones, such as glucagon-like peptide 1, and increases insulin sensitivity, compared with the Roux-en-Y gastric bypass utilising a standard biliopancreatic limb length of 50 cm (‘standard limb’). Objective: To evaluate the mechanisms, clinical efficacy and safety of long limb versus the standard limb Roux-en-Y gastric bypass in patients undergoing metabolic surgery for obesity and diabetes mellitus. Design: A double-blind, mechanistic randomised controlled trial was conducted to evaluate the mechanisms, clinical efficacy and safety of the two interventions. Setting: Imperial College London, King’s College London and their associated NHS trusts. Participants: Patients with obesity and type 2 diabetes mellitus who were eligible for metabolic surgery. Interventions: Participants were randomly assigned (1 : 1) to 150-cm (long limb) or 50-cm (standard limb) biliopancreatic limb Roux-en-Y gastric bypass with a fixed alimentary limb of 100 cm. The participants underwent meal tolerance tests to measure glucose excursions, glucagon-like peptide 1 and insulin secretion, and hyperinsulinaemic–euglycaemic clamps with stable isotopes to measure insulin sensitivity preoperatively, at 2 weeks after the surgery and at matched 20% total body weight loss. Clinical follow-up continued up to 1 year. Main outcome measures: Primary – postprandial peak of active glucagon-like peptide 1 concentration at 2 weeks after intervention. Secondary – fasting and postprandial glucose and insulin concentrations, insulin sensitivity, glycaemic control and weight loss at 12 months after surgery, and safety of participants. Results: Of the 53 participants randomised, 48 completed the trial. There were statistically significant decreases in fasting and postprandial glucose concentrations, increases in insulin, glucagon-like peptide 1 secretion and insulin sensitivity, and reductions in the levels of glycated haemoglobin (i.e. HbA1c) and weight in both long and standard limb groups. However, there were no significant differences between trial groups in any of these parameters. Limitations: The main limitations of this trial include the relatively short follow-up of 12 months and elongation of the biliopancreatic limb to a fixed length of 150 cm. Conclusion: Patients undergoing both types of Roux-en-Y gastric bypass benefited metabolically from the surgery. The results have not demonstrated that elongation of the biliopancreatic limb of the Roux-en-Y gastric bypass from 50 to 150 cm results in superior metabolic outcomes in terms of glucose excursions, insulin and incretin hormone secretion, and insulin sensitivity, when assessed at up to 12 months after surgery. Future work: Continued longitudinal follow-up of the long and standard limb cohorts will be necessary to evaluate any differential effects of the two surgical procedures on patients’ metabolic trajectories. Trial registration: Current Controlled Trials ISRCTN15283219. Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy and Mechanism Evaluation; Vol. 8, No. 3. See the NIHR Journals Library website for further project information. The section in the report on endocrinology and investigative medicine is funded by grants from the Medical Research Council, the Biotechnology and Biological Sciences Research Council, NIHR, an Integrative Mammalian Biology Capacity Building Award and a FP7-HEALTH-2009-241592 EuroCHIP grant. This section is also supported by the NIHR Biomedical Research Centre Funding Scheme.

1 October 2021 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
AKAnna Kamocka
Anna Kamocka
CPChetan Parmar
Chetan Parmar
KKKrzysztof Kurzatkowski
Krzysztof Kurzatkowski
SCSwathikan Chidambaram
Swathikan Chidambaram
EGEn Lin Goh
En Lin Goh
RWRichard Welbourn
Richard Welbourn